Medindia

X

New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care

Saturday, June 5, 2010 General News J E 4
Advertisement
Integrated Analysis Shows Denosumab Superiority Over Zometa(R) In Delaying Or Preventing Skeletal Related Events In Broad Population With Advanced Cancer

CONTACT: Amgen, Thousand Oaks

Lisa Rooney: +1 (805) 559-0739 (media)

Arvind Sood: +1 (805) 447-1060 (investors)

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Denosumab Demonstrated Superiority Over Zometa(R) ...
S
Genomic Health Presents Six New Studies Including ...